Cardiac Amyloidosis

July 11, 2023 | Cardiovascular Business For years, cardiac amyloidosis was a rare and often fatal disease that had no treatment, so it was not front and center in…

The American College of Cardiology (ACC) has a long history of developing documents (eg, decision pathways, health policy statements, appropriate use criteria) to…

The American Society of Nuclear Cardiologyexternal link, opens in a new tab designates this live activity for a maximum of 4 CME Credits(tm). Physicians should…

Amyloidoses are protein-folding disorders in which more than one organ is infiltrated by proteinaceous deposits known as amyloid. The deposits are derived from one…

Cardiac amyloidosis is a form of restrictive infiltrative cardiomyopathy that confers significant mortality. Due to the relative rarity of cardiac amyloidosis,…

Cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved or mildly reduced ejection fraction with emerging treatment options. We…

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac…

Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with a median survival from diagnosis, if untreated, ranging from 6 months…

Purpose of Review The review's main focus centers on the genetics of hereditary cardiac amyloidosis, highlighting the opportunities and challenges posed by the…

Background: Cardiac Amyloidosis (CA) pertains to the cardiac involvement of a group of diseases, in which misfolded proteins deposit in tissues and cause…